Thousand Oaks Biopharmaceuticals, The Integrated CMC Solution Provider Company, delivers solutions that enable your biologics to be accessible and affordable to patients.
Shun Luo Ph.D.
Founder and Chairman
Thousand Oaks Biopharmaceuticals
Thousand Oaks is dedicated to science-based innovation and technology integration.
We have the ultimate goal to enable our partner to deliver more accessibile and affordable biologics to humanity.
How do we measure this?
Manufacturing costs of goods (mCOG), $/kg.
We are excited to lead a group of excellent investors in the direction Thousand Oaks Bio is taking.
TOBIO combines the expertise in cell culture media development, early process development, and full CDMO services to build its high-quality platform for biologics development and manufacturing.
Mr. Liefeng Qu,
Chairman and Partner
New Alliance Capital
Building the world’s largest cell culture manufacturing facility with CDMO capability
Thousand Oaks Biopharmaceuticals Completes $45 Million Series A Financing to Expand Integrated CMC and Build the World Largest Cell Cultural Production Facility in China
January 03, 2019 07:00 AM Eastern Standard Time
THOUSAND OAKS, Calif. & SHANGHAI—(BUSINESS WIRE)—Thousand Oaks Biopharmaceuticals, Inc. (“TOBIO”), a leading integrated global CMC organization including GMP cell culture media and biomanufacturing capabilities today announced the closing of a $45 Million USD Series A financing to advance its phase II CDMO and started its construction of Large Scale Cell Culture Media (LSCCM) cGMP Manufacturing facilities based in Haimen, Nantong (part of greater Shanghai), China.
“Upon completion of the Series A financing, we are pleased that our achievements to date and promising future have been recognized by several renowned investors, including New Alliance Capital, ADDOR Capital, and Tenyall & Sumin. This round of financing allows us to expand our integrated CMC services and to increase current media production capacity by building the world’s largest cell culture medium manufacturing facility,” said Shun Luo, Ph.D., Chairman of TOBIO. “We are very excited about this opportunity to further enhance our capabilities in CMC value chain including cell line development, process and bioanalytical development, and customized cell culture media development, so as to establish an integrated platform from DNA to clinical material supplies and successful regulatory filings, leading towards commercial manufacturing. We are able to establish strategic partnership with customers to effectively accelerate the speed of biologics development from bench to market, benefit patients worldwide. Our goal is to become world class CMC organization enabling our partners to provide affordable and accessible biologics for humanity,” added Dr. Shun Luo.
Globally Experienced Leadership Team
We are working every day to make sure our organization aligns around your needs. From our culture to our processes to our responsiveness we are committed to make you the center of all we do.
Our Integrated CMC Solutions
Our offer includes:
Shanghai, Haimen, & Lanzhou
cGMP Manufacturing and Development Labs